瑞舒伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压的临床效果及安全性  

Clinical efficacy and safety of rosuvastatin in treatment of chronic obstructive pulmonary disease combined with pulmonary hypertension

作　　者：任瑞华[1] 王钧[3] 梁静 雷建华[1] 刘振中[2] Ren Ruihua;Wang Jun;Liang Jing;Lei Jianhua;Liu Zhenzhong(The First Department of Internal Medicine,the Fifth Hospital of Shijiazhuang,Shijiazhuang 050000,China)

机构地区：[1]石家庄市第五医院内一科,050000 [2]石家庄市第五医院感染科,050000 [3]河北省胸科医院呼吸科,石家庄050041

出　　处：《国际呼吸杂志》2018年第22期1724-1727,共4页International Journal of Respiration

摘　　要：目的观察瑞舒伐他汀对慢性阻塞性肺疾病合并肺动脉高压的疗效及不良反应。方法选择2016年1月至2017年6月在石家庄市第五医院治疗的慢性阻塞性肺疾病合并肺动脉高压患者140例,随机分为对照组和观察组,每组70例。对照组采用对症治疗;观察组采用对症治疗联合瑞舒伐他汀。比较2组患者的治疗有效率,以及治疗前后的肺功能、肺动脉压及6分钟步行距离。结果观察组患者的治疗有效率明显高于对照组(91.43%比74.29%,x^2=7.241,P<0.05)。治疗后2组患者的肺动脉收缩压、肺动脉舒张压较治疗前均有明显改善(P值均<0.05),治疗后观察组肺动脉收缩压、肺动脉舒张压均明显低于对照组(t值分别为9.658、10.885,P值均<0.05)。治疗后2组患者的第1秒用力呼气容积、用力肺活量、6分钟步行距离均有明显改善(P值均<0.05),治疗后观察组第1秒用力呼气容积、用力肺活量、6分钟步行距离均明显高于对照组(t值分别为4.893、2.413、3.196,P值均<0.05)。2组患者均未出现严重不良反应。结论瑞舒伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压疗效显著,可有效降低肺动脉压,改善患者肺功能,提高患者6分钟步行距离,且无明显不良反应。Objective To observe the efficacy and adverse effects of rosuvastatin on chronic obstructive pulmonary disease combined with pulmonary hypertension.Methods 140patients with chronic obstructive pulmonary disease combined with pulmonary hypertension treated in the Fifth Hospital of Shijiazhuang from January 2016to June 2017were randomly divided into control group and observation group,70cases in each group.The control group received symptomatic treatment,while the observation group received symptomatic treatment combined with rosuvastatin.The effective rate of the two groups was compared,and the pulmonary function,pulmonary artery pressure,and 6-minute walking distance before and after treatment were compared.Results The effective rate of the observation group was significantly higher than that of the control group (91.43%vs 74.29%,x^2 =7.241,P <0.05). Compared with before treatment,pulmonary artery systolic pressure and pulmonary artery diastolic pressure in the two groups were significantly improved after treatment (all P <0.05).After treatment, pulmonary artery systolic pressure and pulmonary artery diastolic pressure in the observation group were significantly lower than those in the control group (t =9.658,10.885,all P <0.05).Compared with before treatment,the forced expiratory volume in one second,forced vital capacity and 6-minute walking distance in the two groups were significantly improved after treatment (all P <0.05).After treatment,the forced expiratory volume in one second,forced vital capacity and 6-minute walking distance in the observation group were significantly higher than those in the control group (t =4.893,2.413,3.196,all p <0.05).There was no'serious adverse reaction in two groups.Conclusions Rosuvastatin is effective in the treatment of chronic obstructive pulmonary disease combined with pulmonary hypertension.It can effectively reduce pulmonary artery pressure,improve lung function,increase 6-minute walking distance, and has no obvious adverse reactions.

关 键 词：瑞舒伐他汀 慢性阻塞性肺疾病 肺动脉高压 

分 类 号：R563.9[医药卫生—呼吸系统] R544.1[医药卫生—内科学]